Immunohistochemical study of PAX5 expression in lymphoid neoplasms

Wael Abd El Fattah Mohamed Ibrahim Nassar; Ahmed Mohamed Yehia El Hennawy; Samia Mohamed Ahmed Gabal; Mona Salah El-Din Abd El-Magid

doi:10.3889/oamjms.2021.6228

Authors

Wael Abd El Fattah Mohamed Ibrahim Nassar Department of Pathology, Faculty of Medicine, Cairo University, Giza, Egypt https://orcid.org/0000-0002-4913-0776
Ahmed Mohamed Yehia El Hennawy Department of Pathology, Faculty of Medicine, Cairo University, Giza, Egypt
Samia Mohamed Ahmed Gabal Department of Pathology, Faculty of Medicine, Cairo University, Giza, Egypt
Mona Salah El-Din Abd El-Magid Department of Pathology, Faculty of Medicine, Cairo University, Giza, Egypt

DOI:

https://doi.org/10.3889/oamjms.2021.6228

Keywords:

PAX5, B-cell development, B-cell lymphoma, Hodgkin lymphoma

Abstract

ashshdgd

Downloads

Download data is not yet available.

Metrics

Metrics Loading ...

Plum Analytics Artifact Widget Block

References

Jaffe ES, Campo E, Harris NL, Pileri SA, Stein H, Swerdlow SH. Introduction and overview of the classification of lymphoid neoplasms. In: Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, et al, editors. WHO Classification of Tumours of Haematopoietic and Lymphond Tissues. 4th ed. Lyon, France: IARC Press; 2017. p. 190-8. https://doi.org/10.1182/blood-2011-01-293050 DOI: https://doi.org/10.1182/blood-2011-01-293050

Dong HY, Browne P, Liu Z, Garagi M. PAX5 is invariably expressed in B-cell lymphoma without plasma cell differentiation. Histopathology. 2008;53(3):278-87. https://doi.org/10.1111/j.1365-2559.2008.03091.x PMid:18643853 DOI: https://doi.org/10.1111/j.1365-2559.2008.03091.x

Inlay MA, Bhattacharya D, Sahoo D, Serwold T, Seita J, Karsunky H, et al. Ly6d marks the earliest stage of B-cell specification and identifies the break point between B-cell and T cell development. Genes Dev. 2009;23:2376-81. https://doi.org/10.1101/gad.1836009 DOI: https://doi.org/10.1101/gad.1836009

Nutt SL, Kee BL. The transcriptional regulation of B cell lineage commitment. Immunity. 2007;26(6):715-25. https://doi.org/10.1016/j.immuni.2007.05.010 PMid:17582344 DOI: https://doi.org/10.1016/j.immuni.2007.05.010

Lin YC, Jhunjhunwala S, Benner C, Heinz S, Welinder E, Mansson R, et al. A global network of transcription factors, involving E2A, EBF1, and Foxol, that orchestrates B cell fate. Nat Immunol. 2010;11(7):635-43. https://doi.org/10.1038/ni.1891 PMid:20543837 DOI: https://doi.org/10.1038/ni.1891

Medvedovic J, Ebert A, Tagoh H, Busslinger M. PAX5: A master regulator of B cell development and leukemogenesis. Adv Immunol. 2011;111:179-206. https://doi.org/10.1016/b978-0-12-385991-4.00005-2 PMid:21970955 DOI: https://doi.org/10.1016/B978-0-12-385991-4.00005-2

Schebesta A, Mc Manus S, Salvagiotto G, Delogu A, Busslinger GA, Busslinger M. Transcription factor PAX5 activates the chromatin of key genes involved in B cell signaling, adhesion, migration, and immune function. Immunity. 2007;27(1):49-63. https://doi.org/10.1016/j.immuni.2007.05.019 PMid:17658281 DOI: https://doi.org/10.1016/j.immuni.2007.05.019

McManus S, Ebert A, Salvagiotto G, Medvedovic J, Sun Q, Tamir J, et al. The Transcription factor PAX5 regulates its target genes by recruiting chromatin-modifying proteins in committed B cell. EMBO J. 2011;30(12):2388-404. https://doi.org/10.1038/emboj.2011.140 PMid:21552207 DOI: https://doi.org/10.1038/emboj.2011.140

Johnson K, Pflugh DL, Hesslein DG, Link L, Bothwell AL. Thomas-Tikhonenko A, et al. B cell-specific loss of histone 3 lysine 9 methylation in the VH Locus depends on PAX5. Nat Immunol. 2004;5(8):853-61. https://doi.org/10.1038/ni1099 PMid:15258579 DOI: https://doi.org/10.1038/ni1099

Fuxa M, Shok J, Souabni A, Salvagiotto G, Roldan E, Busslinger M. PAX5 induces V-to DJ rearrangements and locus contraction of the immunoglobulin heavy-chain gene. Genes Dev. 2004;18(4):411-22. https://doi.org/10.1101/gad.291504 PMid:15004008 DOI: https://doi.org/10.1101/gad.291504

Rozanski CH, Arens R, Carlson LM, Nair J, Boise LH, Chanan- Khan AA, et al. Sustained antibody responses depend on CD28 function in bone marrow-resident plasma cells. J Exp Med. 2011;208(7):1435-46. https://doi.org/10.1084/jem.20110040 PMid:21690252 DOI: https://doi.org/10.1084/jem.20110040

Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA. WHO Classification of Tumours of Hematopoietic and Lymphoid Tissues. 4th ed. Lyon, France: IARC Press; 2017.

Torlakovic E, Torlakovic G, Nguyen PL, Brunning RD, Delabie J. The value of anti-PAX-5 immunostaining in routinely fixed and paraffin-embedded sections: A novel pan pre-Band B-cell marker. Am J Surg Pathol. 2002;26(10):1343-50. https://doi.org/10.1097/00000478-200210000-00011 PMid:12360049 DOI: https://doi.org/10.1097/00000478-200210000-00011

Chan YH. Biostatistics 102: Quantitative data-parametric and non-parametric tests. Singapore Med J. 2003a;44(8):391-6. PMid:14700417

Chan YH. Biostatistics 103: Qualitative data-tests of independence. Singapore Med J. 2003b;44(10):498-503. PMid:15024452

Barberis A, Widenhorn K, Vitelli L, Busslinger M. Anovel B-cell lineage-specific transcription factor present at early but not late stages of differentiation. Genes Dev. 1990;4(5):849-59. https://doi.org/10.1101/gad.4.5.849 PMid:2116362 DOI: https://doi.org/10.1101/gad.4.5.849

Krenacs L, Himmelmann AW, Quintanilla-Martinez L, Fest T, Riva A, Wellmann A, et al. Transcription factor B-cell specific activator protein (BSAP) is differentially expressed in B-cells and in subsets of B-cell lymphomas. Blood. 1998;92(4):1308-16. https://doi.org/10.1182/blood.v92.4.1308.416k32_1308_1316 PMid:9694719 DOI: https://doi.org/10.1182/blood.V92.4.1308.416k32_1308_1316

Foss HD, Reusch R, Demel G, et al. Frequent expression of the B-cell-specific activator protein in Reed-Sternberg cells of classical Hodgkin’s disease provides further evidence of its B-cell origin. Blood. 1999;94(9):3108-13. https://doi.org/10.1182/blood.v94.9.3108.421a21_3108_3113 PMid:10556196 DOI: https://doi.org/10.1182/blood.V94.9.3108.421a21_3108_3113

Desouki MM, Past GR, cherry D, and Lazerchick J. PAX5: A valuable immunohistochemical marker in the differential diagnosis of lymphoid neoplasms. Clin Med Res. 2010;8(2):84- 8. https://doi.org/10.3121/cmr.2010.891 PMid:20660931 DOI: https://doi.org/10.3121/cmr.2010.891

Madanagopaal LR, Subashchandrabose P, Sivanandam S. Analysis of PAX5 expression of Hodgkin’s and non-Hodgkin’s lymphomas in comparison with routine panel. Arch Cyto Histopathol Res. 2016;1(1):4-13.